Research Article
Effect of Tofogliflozin on Body Composition and Glycemic Control in Japanese Subjects with Type 2 Diabetes Mellitus
Table 2
Evaluation about the efficacy of tofogliflozin on body composition using InBody.
| | Parameters | Baseline | 4 weeks | | 12 weeks | |
| | Body fat mass (kg) | 33.7 ± 1.7 | 32.3 ± 1.9 (−1.4) | <0.01 | 31.8 ± 1.8 (−2.9) | <0.01 | | Skeletal muscle mass (kg) | 29.8 ± 1.2 | 29.3 ± 1.2 (−0.5) | <0.05 | 29.0 ± 1.1 (−0.8) | <0.01 | | Skeletal muscle mass of extremities (kg) | M: 25.9 ± 0.8
F: 17.1 ± 0.8 | 25.5 ± 0.9
17.1 ± 0.8 | <0.01
n.s. | 25.2 ± 0.8
16.5 ± 0.9 | <0.01
<0.01 | | Skeletal muscle index (kg/m2) | M: 9.1 ± 0.2
F: 7.0 ± 0.3 | 8.9 ± 0.2
7.0 ± 0.3 | <0.01
n.s. | 8.9 ± 0.2
6.9 ± 0.3 | <0.01
<0.01 | | Soft lean mass (kg) | 53.4 ± 1.9 | 52.4 ± 2.0 (−1.0) | <0.01 | 52.4 ± 1.8 (−1.0) | <0.01 | | Visceral fat area (cm2) | 157.7 ± 8.0 | 152.1 ± 9.0 (−5.6) | <0.01 | 150.5 ± 8.7 (−7.2) | <0.01 | | Total body water (kg) | 39.5 ± 1.4 | 38.7 ± 1.4 (−0.8) | <0.05 | 38.6 ± 1.4 (−0.9) | <0.01 | | Intracellular water (kg) | 24.3 ± 0.9 | 23.8 ± 0.9 | <0.01 | 23.8 ± 0.9 | <0.01 | | Extracellular water (kg) | 15.1 ± 0.5 | 14.8 ± 0.5 | <0.05 | 14.8 ± 0.5 | <0.05 |
|
|
